{
    "Trade/Device Name(s)": [
        "DRI Ecstasy Plus Assay",
        "DRITM Ecstasy Plus Assay"
    ],
    "Submitter Information": "Microgenics Corporation",
    "510(k) Number": "K240670",
    "Predicate Device Reference 510(k) Number(s)": [
        "K012110"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DKZ"
    ],
    "Summary Letter Date": "October 30, 2024",
    "Summary Letter Received Date": "October 4, 2024",
    "Submission Date": "March 8, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.3100"
    ],
    "Regulation Name(s)": [
        "Amphetamine test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Ecstasy",
        "3,4-methylenedioxyamphetamine (MDA)",
        "3,4-methylenedioxymethamphetamine (MDMA)",
        "3,4-methylenedioxyethylamphetamine (MDEA)"
    ],
    "Specimen Type(s)": [
        "Human urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Abbott Architect C4000"
    ],
    "Method(s)/Technology(ies)": [
        "Homogeneous enzyme immunoassay"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for DRI Ecstasy Plus Assay for qualitative or semiquantitative detection of ecstasy drugs in human urine using homogeneous enzyme immunoassay.",
    "Indications for Use Summary": "Intended for the qualitative or semiquantitative determination of ecstasy drugs in human urine at a cutoff level of 500 ng/mL; for use in clinical laboratories only as a screening procedure, with confirmatory testing recommended.",
    "fda_folder": "Toxicology"
}